78 related articles for article (PubMed ID: 10902827)
1. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium.
Casele HL; Laifer SA
J Matern Fetal Med; 2000; 9(2):122-5. PubMed ID: 10902827
[TBL] [Abstract][Full Text] [Related]
2. Bone density changes in women who receive thromboprophylaxis in pregnancy.
Casele H; Haney EI; James A; Rosene-Montella K; Carson M
Am J Obstet Gynecol; 2006 Oct; 195(4):1109-13. PubMed ID: 17000242
[TBL] [Abstract][Full Text] [Related]
3. Enoxaparin treatment in women with mechanical heart valves during pregnancy.
Rowan JA; McCowan LM; Raudkivi PJ; North RA
Am J Obstet Gynecol; 2001 Sep; 185(3):633-7. PubMed ID: 11568791
[TBL] [Abstract][Full Text] [Related]
4. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
[TBL] [Abstract][Full Text] [Related]
5. Effect of bed rest during pregnancy on bone turnover markers in pregnant and postpartum women.
Kaji T; Yasui T; Suto M; Mitani R; Morine M; Uemura H; Maeda K; Irahara M
Bone; 2007 Apr; 40(4):1088-94. PubMed ID: 17229597
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
Narin C; Reyhanoglu H; Tülek B; Onoglu R; Ege E; Sarigül A; Yeniterzi M; Durmaz I
Adv Ther; 2008 Jun; 25(6):585-94. PubMed ID: 18568442
[TBL] [Abstract][Full Text] [Related]
7. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin.
Gates S; Brocklehurst P; Ayers S; Bowler U;
Am J Obstet Gynecol; 2004 Oct; 191(4):1296-303. PubMed ID: 15507957
[TBL] [Abstract][Full Text] [Related]
8. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study.
Lange U; Teichmann J; Müller-Ladner U; Strunk J
Rheumatology (Oxford); 2005 Dec; 44(12):1546-8. PubMed ID: 16263785
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy.
Pauzner R; Dulitzki M; Langevitz P; Livneh A; Kenett R; Many A
Thromb Haemost; 2001 Dec; 86(6):1379-84. PubMed ID: 11776303
[TBL] [Abstract][Full Text] [Related]
10. Influence of long-term thromboprophylaxis with low-molecular-weight heparin (enoxaparin) on changes of bone metabolism markers in pregnant women.
Sudrová M; Kvasnička J; Kudrnová Z; Zenáhlíková Z; Mazoch J; Brzežková R
Clin Appl Thromb Hemost; 2011 Oct; 17(5):508-13. PubMed ID: 20682598
[TBL] [Abstract][Full Text] [Related]
11. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae. The pilot randomised controlled NOH-AP trial.
Gris JC; Chauleur C; Faillie JL; Baer G; Marès P; Fabbro-Peray P; Quéré I; Lefrant JY; Haddad B; Dauzat M
Thromb Haemost; 2010 Oct; 104(4):771-9. PubMed ID: 20694277
[TBL] [Abstract][Full Text] [Related]
12. Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves.
Izaguirre R; De La Peña A; Ramírez A; Cortina E; Huerta M; Salazar E
Proc West Pharmacol Soc; 2002; 45():127-8. PubMed ID: 12434554
[No Abstract] [Full Text] [Related]
13. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk.
Nelson-Piercy C; Letsky EA; de Swiet M
Am J Obstet Gynecol; 1997 May; 176(5):1062-8. PubMed ID: 9166169
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of fondaparinux versus enoxaparin treatment in women with infertility or pregnancy loss.
Winger EE; Reed JL
Am J Reprod Immunol; 2009 Oct; 62(4):253-60. PubMed ID: 19703143
[TBL] [Abstract][Full Text] [Related]
15. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy.
Lebaudy C; Hulot JS; Amoura Z; Costedoat-Chalumeau N; Serreau R; Ankri A; Conard J; Cornet A; Dommergues M; Piette JC; Lechat P
Clin Pharmacol Ther; 2008 Sep; 84(3):370-7. PubMed ID: 18431408
[TBL] [Abstract][Full Text] [Related]
16. Heparin-induced osteoporosis and pregnancy.
Le Templier G; Rodger MA
Curr Opin Pulm Med; 2008 Sep; 14(5):403-7. PubMed ID: 18664969
[TBL] [Abstract][Full Text] [Related]
17. Bed rest and other determinants of bone loss during pregnancy.
Promislow JH; Hertz-Picciotto I; Schramm M; Watt-Morse M; Anderson JJ
Am J Obstet Gynecol; 2004 Oct; 191(4):1077-83. PubMed ID: 15507924
[TBL] [Abstract][Full Text] [Related]
18. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
19. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
[TBL] [Abstract][Full Text] [Related]
20. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
